The partnership between Sanofi and CytoReason – for an undisclosed, multimillion dollar amount – forms part of an ongoing collaboration begun in 2021, which originally focused on obtaining advanced mechanistic insights for asthma endotypes. The collaboration takes CytoReason’s partnering with leading pharmaceutical companies to a total of five.
CytoReason develops computational disease models. Through use of precision medicine and machine learning (ML), the company’s cell-centred models will aid identification of patient subtypes and pair them with personalised IBD targets. Its AI-led platform aims to turn biological disease models into actionable insights that enable shortened clinical trials, a reduction in drug development costs, identification of new opportunities, and an increased likelihood of drug approval.
